Previous Close | 0.4000 |
Open | 0.2000 |
Bid | 0.0000 |
Ask | 0.0000 |
Strike | 5.00 |
Expire Date | 2024-05-17 |
Day's Range | 0.2000 - 0.4000 |
Contract Range | N/A |
Volume | |
Open Interest | N/A |
The focus is likely to be on progress on its pipeline candidates when generative AI drug creation company Absci (ABSI) reports first-quarter results.
CytomX Therapeutics (CTMX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
VANCOUVER, Wash. and NEW YORK, April 16, 2024 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a data-first generative AI drug creation company, today announced the company will report business updates and financial and operating results for the first quarter before market open on Tuesday, May 14, 2024. Absci management will webcast a corresponding conference call beginning at 8:00 a.m. Eastern Time / 5:00 a.m. Pacific Time to discuss its business developments, financial and operating resul